tbuckley/cabot-search huggingface dataset:
breast cancer, early stage Interim results from neoMONARCH: A neoadjuvant phase II study of abemaciclib in postmenopausal women with HR + /HER2- breast cancer (BC)
Authors: S. Hurvitz, M.F. Abad, R. Rostorfer, D. Chan, D. Egle, C.-S. Huang, S. Barriga, T.M. Costigan, C.W. Caldwell, J.M. Schilder, M.F. Press, D. Slamon, M. Martin
Journal: Annals of Oncology (2016)
Association of single-nucleotide polymorphisms in <i>BCL2L1</i> and <i>TACC3</i> with response to bacillus Calmette-Guérin intravesical therapy in non-muscle-invasive bladder cancer.
Authors: Shaheen Alanee, David James Gallagher, Joseph Vijai, Robert James Hamilton, Irina Ostrovnaya, Ilana Rebecca Garcia-Grossman, Jamie C. Riches, Ashley Marie Regazzi, Jennifer A. Przybylo, Mia Gaudet, Matthew I. Milowsky, Harry W. Herr, Kenneth Offit, Dean F. Bajorin
Journal: Journal of Clinical Oncology (2012)

260 Background: Bacillus Calmette-Guérin intravesical therapy (BCG) has an important role in the management of high risk non-muscle-invasive bladder cancer (NMIBC). This study examines the association between germline single nucleotide polymorphisms (SNPs) and response to BCG therapy. Methods: Saliva or blood was collected from pts with NMIBC treated at a single center and diagnosed between 1984 and 2010. SNPs were selected based on reported associations with bladder cancer and BCG response, and genotyped using the Sequenom MassARRAY iPLEX system. No response to BCG was defined as the presence at 6 months of pathologically documented tumor in the bladder. Univariate logistic regression was used to test the association between the outcome of interest (no response to BCG at 6 months) and clinical variables (stage, grade and multifocality), or individual SNPs. Results: The cohort consisted of 158 pts with a median age of 65 years who received intravesical BCG for NMIBC (35.2% stage T1, 32.7% stage Ta and 31.4% stage Tis) with 93% having high-grade disease. At 6 months follow up, 22 (13.9%) patients showed no response to BCG. We successfully genotyped 80 of the 88 selected SNPs. Of these, 2 SNPs were associated with lack of response to BCG; rs798766 is an intronic SNP in TACC3 (OR for no response is 2.4 for each T allele relative to CC genotype, P=0.01), and rs1994251 an intronic SNP in BCL2L1 (OR for no response is 3.2 for each C allele relative to AA, p= 0.0008). Both SNPs remained significantly associated with lack of response after adjusting for predictive clinical variables. Conclusions: Single nucleotide polymorphisms of BCL2L1 and TACC3 may be predictive of BCG refractory bladder cancer. Future validation studies on independent datasets are needed to determine the clinical utility of these findings.
Proceedings of the British Thoracic Society
Journal: Thorax (1992)

At the time of entry medical examination students at Queen's University Belfast complete a health screening questionnaire.This includes questions relating to cough, dyspnoea and the presence of a current diagnosis of asthma.The medical notes of all students between 18 and 21 years old with self reported asthma (n = 339) and an equal number of matched controls were reviewed for these symptoms, for a history suggestive of atopy and the 209P on August 30, 2023 by guest.
The JAK2 V617F Mutation Is Uncommon in Patients with Juvenile Myelomonocytic Leukemia.
Authors: Nao Yoshida, Hiroshi Yagasaki, Yinyan Xu, Tomoko Yamamoto, Kazuko Kudo, Koji Kato, Keizo Horibe, Atsushi Manabe, Seiji Kojima
Journal: Blood (2005)
Flow cytometric quantification of surface IGF-1R and intracellular p-AKT, p-S6, and p-ERK in Ewing sarcoma (EWS) cells.
Authors: Steven G. DuBois, C. Lorrie Epling, Alice Tan, Katherine K. Matthay, Elizabeth Sinclair
Journal: Journal of Clinical Oncology (2012)

23 Background: Targeting the IGF-1R pathway has shown preclinical and clinical evidence of activity in EWS. Markers predictive of response to IGF-1R inhibition are required. The aims of the current study were to quantify surface IGF-1R expression and intracellular signaling proteins by flow cytometry. Methods: Flow cytometry for CD99 and CD45 was used to detect bone marrow micrometastatic tumor cells as CD99+CD45- events in patients with localized EWS. Surface IGF-1R was quantified on tumor cells and normal marrow cells using a commercially available antibody. RD-ES EWS cells were spiked into control PBMCs and starved for 1 hour. Cells were then treated with saline control, rapamycin 10 ng/mL, ADW742 5 uM (small molecule IGF-1R inhibitor), or alpha-IR3 0.5 ug/mL (anti-IGF-1R antibody) and levels of pS6, pAKT, and pERK quantified by phospho-flow cytometry 60 minutes later. All results were expressed as the mean fluorescent intensity (MFI) of staining using arbitrary units. Results: We detected bone marrow micrometastatic tumor cells in marrow samples from 16 patients with EWS. We observed heterogeneous levels of IGF-1R tumor cell surface expression between patients (range of IGF-1R MFI = 0 – 3355). IGF-1R levels were higher in CD99+CD45- tumor cells compared to normal marrow cells (mean MFI 840 for CD99+CD45- tumor cells vs.190 for normal marrow cells; p = 0.005). In RD-ES cells spiked into PBMCs, treatment with rapamycin resulted in 1.32 fold increase in pAKT MFI compared to saline control. Treatment with ADW742 or alpha-IR3 did not impact pAKT MFI. Treatment with rapamycin resulted in a 0.52 fold decrease and a 1.20 fold increase in pS6 and pERK, respectively. Treatment with ADW742 or alpha-IR3 each resulted in similar decreases in both pS6 (0.75-0.87 fold) and pERK (0.67-0.82 fold). In PBMCs, modest changes in pS6 in rapamycin treated cells were observed, without changes in pAKT or pERK. Neither ADW742 nor alpha-IR3 modulated pS6, pAKT, or pERK signaling in PBMCs. Conclusions: Flow cytometry detects a range of surface IGF-1R expression on bone marrow micrometastatic EWS cells. Phospho-flow cytometry detects modulation of pAKT, pS6, and pERK in EWS cells treated with IGF-1R or mTOR inhibitors.
Ex-Vivo UVA Treated Donor T-Cells for the Induction of Graft Versus Leukemia Effect in Murine Model and Clinical Application
Authors: Si mcha Samuel, Lola Weiss, Osnat Hazan, Igor B Resnick, Michael Y. Shapira, Benjamin Gesundheit, Lilane Dray, Reuven Or
Journal: Blood (2008)
The incidence and relative risk of pulmonary toxicity (PT) in patients treated with anti-PD-1/PD-L1 targeted therapies for solid tumors
Authors: C. Ciccarese, R. Iacovelli, A. Modena, D. Bimbatti, E. Fantinel, M. Brunelli, E. Bria, G. Tortora
Journal: Annals of Oncology (2016)
Dual-Color CRBN/CD138 Immunohistochemistry Assay for Measuring Cereblon Protein in Samples from Patients with Multiple Myeloma
Authors: Yan Ren, Maria Wang, Suzanne Couta, Donna Hansel, Karen Miller, Antonia Lopez-Girona, Chad C Bjorklund, Anita K. Gandhi, Anjan Thakurta, Rajesh Chopra, Michael Breider
Journal: Blood (2014)
NIMG-57. BOLD fMRI REFLECTS THE LOCAL PRESENCE OF GLIOBLASTOMA
Authors: Stephen Bowden, Brian Gill, George Zanazzi, Zachary Englander, Jorge Samanamud, Jeffrey Bruce, Peter Canoll, Jack Grinband
Journal: Neuro-Oncology (2016)

Glioblastoma (GBM)-induced breakdown of the blood brain barrier is revealed by contrast enhancement (CE) on MRI and corresponds to the presence of bulk tumor tissue. However, vascular function in the CE area and the surrounding, non-enhancing (NE) area of infiltrating glioma cells is less defined. Resting-state BOLD (Blood Oxygen Level Dependent) fMRI has been shown to be sensitive to alterations in neurovascular coupling both within and outside the region of CE in GBM. However, the mechanism by which the tumor disrupts vascular control in these areas is not known. We hypothesize that the alterations in neurovascular coupling seen in GBM are due to the local effects of infiltrating glioma cells. To test this hypothesis, we took 25 radiographically-localized biopsies from CE (n=16) and NE (n=9) regions during open surgical resection of primary GBM in patients with pre-operative resting-state BOLD fMRI. The BOLD scan was co-registered to the volumetric T1-weighted + gadolinium scan used for intraoperative stereotactic guidance and the BOLD signal intensity was calculated from a spherical region of interest (radius=2 mm) at each biopsy site. Cellularity of each sample was calculated by averaging cell counts from three high powered fields of highest cellularity on H&E stained sections. Linear robust regression was used to evaluate the relationship between mean signal intensity and cellularity. The BOLD signal intensity was positively correlated to tissue cellularity (correlation coefficient = 0.42, p<0.01), indicating that the neurovascular coupling mechanism is disrupted by local effects of glioma cells. Moreover, this result suggests that BOLD fMRI could serve as a clinically useful biomarker for glioma infiltration into non-contrast-enhancing brain regions.
Randomized phase II study of maintenance irinotecan therapy versus observation following induction chemotherapy with irinotecan and cisplatin in extensive disease small cell lung cancer (ED-SCLC)
Authors: J. Han, K. Lim, S. Yoon, H. Kim, J. Han, H. Kim, J. Lee
Journal: Journal of Clinical Oncology (2008)

8093 Background: Irinotecan has been demonstrated to have significant activity against SCLC. To determine whether irinotecan maintenance therapy in ED-SCLC can further improve survival of patients who responded to irinotecan plus cisapltin (IP) induction-therapy. Methods: A total of 120 chemo-naïve patients with adequate organ functions and ECOG PS of 0–2 were enrolled from March 2003 through April 2006. After IP induction-therapy, with either schedule A (I: 60 mg/m2 IV on days 1, 8, and 15; P: 30 mg/m2 IV on days 1 and 8, every 4 weeks for 6 cycles) or schedule B (I: 60 mg/m2 and P: 30 mg/m2 IV on days 1, and 8, every 3 weeks for 8 cycles), responding patients were randomized to either maintenance with irinotecan 100 mg/m2 IV on days 1, 8, and 15, every 4 weeks up to 6 cycles, or observation. Results: Overall, 100 (83%) of 120 patients achieved objective tumor responses (12 CR, 88 PR) after IP induction-therapy. Of those patients who remained in remission upon completion of planned cycles of induction-therapy, 45 were randomized to maintenance (n=21) or observation (n=24). Median PFS and OS for all patients were 7.2 and 14.0 months, respectively. For the maintenance arm, median PFS and OS were 12.0 and 17.6 months, respectively. For the observation arm, median PFS and OS were 9.9 and 20.5 months, respectively, which was not significantly different from the maintenance arm. Conclusions: IP chemotherapy is very useful for the treatment of SCLC. However, maintenance irinotecan therapy did not seem to further affect the clinical outcome of patients who had responded to IP induction-therapy (supported in part by NCC grants 0510140 and 0510080). No significant financial relationships to disclose.
1PD Breast cancer blood-derived exosomes: Characterisation of protein composition in search for new biomarkers
Authors: O.S. Tutanov, S.N. Tamkovich, A. Grigoryeva, E. Ryabchikova, T. Duzhak, Y. Tsentalovich, P. Laktionov, V. Vlassov
Journal: Annals of Oncology (2016)
Doctor, what are my options? A prospective cohort study of an individualized care plan for patients with gastrointestinal cancer.
Authors: Amanda E. Hird, Madeline Lemke, Miriam Turovsky, Carlo DeAngelis, Edward Chow, Yoo-Joung Ko
Journal: Journal of Clinical Oncology (2012)

12 Background: For new cancer patients, information about the complexity of the disease, treatment schedule and potential side effects is often delivered during an emotional, stressful visit which can lead to misunderstanding. Appropriate informational support can improve informed decision making, adherence to treatment, and reduce anxiety and cancer morbidity. This is a 3-part clinical study investigating the utility of a patient-centered individualized care plan for patients with gastrointestinal (GI) cancer starting a new treatment. Methods: Part 1: Items identified in a comprehensive literature search were formatted into a questionnaire. For each item, participants ranked its importance. Part 2: MDs and RNs involved in the care of patients with GI cancer provided comments about the content of the care plan. Part 3: A prospective cohort study was conducted. During the first 10-weeks, patients received the standard of care. During the subsequent 10-weeks, patients received the intervention, a written individualized care plan. Outcomes were assessed at baseline and 2-4 weeks: QOL (FACT-G), anxiety and depression (HADS), treatment compliance and patient satisfaction (FACT-TS-PS). Results: Part 1: 73 items were included in the questionnaire. 20 patients completed the interview. Part 2: A long and short version of the care plan were created. The majority of MDs and RNs preferred the long version. Based on the comments, the final version was created. Part 3: 54 and 41 patients have been enrolled in the control and intervention cohorts, respectively. Analysis of the baseline data revealed fewer self-reported anxious (p=0.008) and depressive symptoms (p=0.002) in the intervention group. The nursing satisfaction score was significantly higher in the intervention group (7.09 vs. 4.80, p=0.018). Overall QOL and satisfaction scores were higher in the intervention group, but not statistically significant (81.30 vs. 76.25, 79.70 vs. 76.27). Conclusions: The care plan resulted in fewer anxious and depressive symptoms. There was a trend towards improved QOL and satisfaction in the intervention group, although not significant. We are continuing to enroll patients and analyze follow-up data.
Untargeted next-generation sequencing-based first-line diagnosis of infection in immunocompromised adults: a multicentre, blinded, prospective study
Authors: P. Parize, E. Muth, C. Richaud, M. Gratigny, B. Pilmis, A. Lamamy, J.-L. Mainardi, J. Cheval, L. de Visser, F. Jagorel, L. Ben Yahia, G. Bamba, M. Dubois, O. Join-Lambert, M. Leruez-Ville, X. Nassif, A. Lefort, F. Lanternier, F. Suarez, O. Lortholary, M. Lecuit, M. Eloit
Journal: Clinical Microbiology and Infection (2017)
F<scp>ifty</scp>Y<scp>ears</scp><scp>of</scp>R<scp>esearch</scp><scp>in</scp>ARDS.Setting Positive End-Expiratory Pressure in Acute Respiratory Distress Syndrome
Authors: Sarina K. Sahetya, Ewan C. Goligher, Roy G. Brower
Journal: American Journal of Respiratory and Critical Care Medicine (2017)

Positive end-expiratory pressure (PEEP) has been used during mechanical ventilation since the first description of acute respiratory distress syndrome (ARDS). In the subsequent decades, many different strategies for optimally titrating PEEP have been proposed. Higher PEEP can improve arterial oxygenation, reduce tidal lung stress and strain, and promote more homogenous ventilation by preventing alveolar collapse at end expiration. However, PEEP may also cause circulatory depression and contribute to ventilator-induced lung injury through alveolar overdistention. The overall effect of PEEP is primarily related to the balance between the number of alveoli that are recruited to participate in ventilation and the amount of lung that is overdistended when PEEP is applied. Techniques to assess lung recruitment from PEEP may help to direct safer and more effective PEEP titration. Some PEEP titration strategies attempt to weigh beneficial effects on arterial oxygenation and on prevention of cyclic alveolar collapse with the harmful potential of overdistention. One method for PEEP titration is a PEEP/Fi
An explorative analysis of <i>TOP1</i> copy number alterations in a chemonaive stage III CRC patient cohort.
Authors: David Hersi Smith, Maria Unni Rømer, Niels Frank Jensen, Sune Boris Nygaard, Ib Jarle Christensen, Sven Müller, Hans J. Nielsen, Nils Brunner, Kirsten Vang Nielsen
Journal: Journal of Clinical Oncology (2012)

66 Background: Topoisomerase I (TOP1) is the target of TOP1 inhibitor chemotherapy. The TOP1 gene, located at 20q12, is frequently gained in colorectal cancer (CRC). The present study explores the mechanism, frequency and prognostic impact of TOP1 gene alterations in advanced CRC. Methods: Nine CRC cell line metaphase spreads were analyzed with a TOP1 probe in combination with a reference probe covering either the centromeric region of chromosome 20 (CEN20) or chromosome 2 (CEN2). Tissue sections from 154 stage III CRC patients, previously studied with TOP1/CEN20, were analyzed with TOP1/CEN2. Relationships between biomarker status and overall survival (OS), time to recurrence (TTR) in CRC and to local recurrence (LR; rectal cancer only) were analyzed using multivariate statistics. Results: TOP1 alterations were observed in 4 cell line metaphases. In 3 cases, TOP1 gain involved CEN20, indicating either gain of chromosome 20 or 20q. In all cell lines CEN2 was found to reflect chromosomal ploidy levels and therefore the TOP1/CEN2 probe combination was selected to identify TOP1 gene gains (TOP1/CEN2 ratio ≥ 1.5). A total of 151 patient tumor sections were analyzed with TOP1/CEN2. Among these, 99 patients (65.6%) had TOP1 gain of which 15 patients (10 %) harbored TOP1 amplification (TOP1/CEN20 ratio ≥ 2.0). For OS, TOP1 amplification showed a trend towards longer OS and TTR (HR: 0.59; 95% CI: 0.31-1.14; p = 0.11; HR: 0.50; 95% CI: 0.23-1.09; p = 0.08; respectively), whereas TOP1 gain did not. For LR in rectal cancer patients (n=70), TOP1 gains were significantly associated with shorter time to LR (HR: 1.98, 95% CI: 1.02-3.84; p = 0.04), whereas TOP1 amplifications showed a trend towards longer time to LR (HR: 0.40; 95% CI: 0.14-1.11; p = 0.08). Conclusions: TOP1 gene gain occurs frequently in stage III CRC in a mechanism that often includes CEN20. Using CEN2 as a measurement for tumor ploidy levels, we were able to discriminate between gains and amplifications. TOP1 amplifications showed a trend towards longer OS, TTR and time to LR, whereas TOP1 gains were associated with shorter time to LR. Future studies will investigate the difference between TOP1 gains and amplifications in a larger TOP1 inhibitor treated patient population.
Mentee Missteps
Authors: Valerie Vaughn, Sanjay Saint, Vineet Chopra
Journal: JAMA (2017)

Mentorship takes many forms, from personal and professional counseling to clinical and research guidance. The wisdom and guidance of experienced mentors not only help mentees ascend the academic ladder, but may also prevent burnout. Given the importance of this relationship, it is imperative that mentees put their “best foot forward.” Unfortunately, young physicians are rarely taught what is expected of them as mentees, and mentors vary in discussing “menteeship” with proteges.
First-in-human phase 1, dose-escalation and -expansion study of ABBV-399, an antibody-drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors
Authors: E. Angevin, K. Kelly, R. Heist, D. Morgensztern, C. Weekes, T.M. Bauer, R.K. Ramanathan, J. Nemunaitis, X. Fan, O. Olyaie, A. Parikh, E. Reilly, D. Afar, L. Naumovski, J. Strickler
Journal: Annals of Oncology (2016)
Henri Rendu and His Contributions to Dermatology and Neurology
Authors: Ahmed Kashkoush, Devan Patel, Arpan V. Prabhu, Thomas G. Benedek
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy
Authors: Timothy M. Cox, Guillermo Drelichman, Renata Cravo, Manisha Balwani, Thomas Andrew Burrow, Ana Maria Martins, Elena Lukina, Barry Rosenbloom, Ozlem Goker-Alpan, Nora Watman, Amal El-Beshlawy, Priya S. Kishnani, Maria Lucia Pedroso, Sebastiaan J. M. Gaemers, Regina Tayag, M. Judith Peterschmitt
Journal: Blood (2017)
Updated efficacy and safety from the global phase II NP28673 study of alectinib in patients (pts) with previously treated ALK+ non-small-cell lung cancer (NSCLC)
Authors: F. Barlesi, A.-M.C. Dingemans, J.C.-H. Yang, S.-H.I. Ou, J.S. Ahn, L. De Petris, B. Hughes, H. Lena, W. Bordogna, S. Golding, P.N. Morcos, B. Balas, A. Zeaiter, D.-W. Kim
Journal: Annals of Oncology (2016)
Prolonging the Incubation of Monocytes with GM-CSF and IL-4 for More Than 3 Days during the Generation of Dendritic Cells (DCS) In Vitro Markedly Diminishes IL-12 and Increases IL-10 Production When DCS Are Subsequently Matured.
Authors: Abdul Tawab, Yong Fan, Thao Mai, Elizabeth J. Read, Roger J. Kurlander
Journal: Blood (2006)
Proactive approach to risk reduction and early detection of breast cancer-related lymphedema.
Authors: Mei R. Fu, Amber Guth, Robin Kleinman, Francis Cartwright, Deborah M. Axelrod
Journal: Journal of Clinical Oncology (2012)

95 Background: Advances in surgery and post-operative treatment continue to reduce the incidence of late effects of cancer treatment such as lymphedema. Yet, many breast cancer survivors still face considerable post-operative challenges as a result of developing lymphedema. The purpose of this study was to preliminarily evaluate an educational and behavioral program “The Optimal YOU” to enhance lymphedema risk reduction among patients with breast cancer. The intervention focuses on preventing inflammation-infection, promoting lymph drainage, and maintaining optimal BMI as well as preoperative and subsequent follow-up assessment of limb volume changes and symptoms. Methods: A quasi-experimental design with repeated-measures was used to assess outcomes of The Optimal YOU program at pre-operative baseline, post-operative, 6-month, and 12-month follow-up. A total of 147 patients newly diagnosed with breast cancer were recruited and received the program. The program outcome data include lymph volume changes by infra-red perometer-S350, lymphedema-related symptoms by Lymphedema Symptom Experience Index, and body mass index (BMI) by Bioimpedance DF50. Results: Among the 147 patients, 141 patients completed the study (4% attrition rate). Majority (94%) of patients maintained preoperative limb volume and improved their symptom experience at 12-month follow-up. During the 12-month study period, only five patients (6%) developed lymphedema and were referred for lymphedema treatment. At 12-month follow-up, among the five patients who developed measurable lymphedema, two patients’ limb volume returned to pre-operative level without compression therapy only by maintaining exercises of The Optimal YOU to promote daily lymph flow. About 80% of patients maintained or improved their preoperative BMI. Conclusions: The study shows that proactive approach to implementing The Optimal YOU program is effective to risk reduction and early detection of breast cancer-related lymphedema by focusing on preventing inflammation-infection, promoting lymph drainage, and maintaining optimal BMI.
Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT
Authors: Robert Chen, Joycelynne Palmer, Peter Martin, Saro Armenian, Nichun Tsai, Michelle Mott, Firoozeh Sahebi, Ji-Lian Cai, Tanya Siddiqi, Leslie L. Popplewell, John P. Leonard, Auayporn P. Nademanee, Steven T. Rosen, Larry W. Kwak, Stephen J. Forman
Journal: Blood (2015)